Form 4 for WST West Pharmaceutical Services
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0001127602-24-007632 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-29 | 2024-02-27 | WST | Green Eric Mark | Pres, CEO, Board COB, Dir | S - Sale+OE | $359.85 | -64.1K | 152.9K | -30% | -$23.08M |
| DM | 2024-02-29 | 2024-02-27 | WST | Green Eric Mark | Pres, CEO, Board COB, Dir | M - OptEx | $57.38 | +73.1K | 152.9K | +92% | +$4.20M |
| DM | 2024-02-29 | 2024-02-27 | WST | Green Eric Mark | Pres, CEO, Board COB, Dir | M - OptEx | $0.00 | -73.1K | 9,316 | -89% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-27 | S | D | 64,132 | $359.85 | 152,908.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. (F2) The price reported in Column 4 is a weighted average price. |
| 2 | Common | Common Stock | 2024-02-27 | M | A | 64,132 | $57.38 | 217,040.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. |
| 3 | Common | Common Stock | 2024-02-27 | M | A | 9,000 | $57.38 | 152,908.12 | D | — | — | (F1) The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023. |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-02-27 | M | D | 64,132 | $0.00 | 15,684 | D | $57.38 · 2016-02-23 to 2025-04-24 | 64,132 Common Stock | |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-02-27 | M | D | 9,000 | $0.00 | 9,316 | D | $57.38 · 2015-04-24 to 2025-04-24 | 9,000 Common Stock |